EUROLAB
usp-1031-the-biocompatibility-of-materials-and-impurities
Impurity Profiling EMA Guideline on Genotoxic Impurities in PharmaceuticalsEMA Reflection Paper on Low Level ImpuritiesFDA Guidance: Microbial Impurities and Endotoxin LevelsFDA Guidance: Threshold of Toxicological Concern (TTC) for ImpuritiesFDA ICH M3(R2): Impurities in Safety StudiesFDA Q&A on Impurities in Generic Drug ApplicationsFDA Q&A: Managing Impurities in Complex APIsICH E14: QT Interval Evaluation and Impurity ImpactICH M7: Mutagenic Impurity Risk AssessmentICH Q10: Pharmaceutical Quality System for Impurity ManagementICH Q11: Impurity Control Strategy in Drug Substance DevelopmentICH Q12: Lifecycle Management of Impurity Control StrategyICH Q1E: Evaluation of Stability Data Related to Impurity FormationICH Q2(R1): Validation of Analytical Methods for Impurity TestingICH Q3A: Organic Impurity Profiling in Drug SubstancesICH Q3B: Impurity Testing in Finished Drug ProductsICH Q3C: Residual Solvent ProfilingICH Q3D: Elemental Impurity Risk AssessmentICH Q3F: Impurity Guidelines for Biotechnology ProductsICH Q4B: Harmonization of Analytical Procedures for Impurity TestingICH Q5C: Impurity Monitoring in Biotechnological ProductsICH Q6A: Specifications and Acceptance Criteria for ImpuritiesICH S3A: Impurities Arising from Degradation ProductsICH S6: Biotech Product Impurity ProfilingICH S7A: Safety Pharmacology Impurity EvaluationICH S9: Impurities in Oncology ProductsISO 10993-18: Chemical Characterization and Impurity AnalysisISO 17025: Accreditation for Impurity Testing LaboratoriesJP General Rule 2.60: Limit Test for ImpuritiesPh. Eur. 2.2.28: Gas Chromatography for Impurity DetectionPh. Eur. 2.2.38: Thin-Layer Chromatography for ImpuritiesPh. Eur. 2.2.46: Chromatographic Separation for Impurity AnalysisPh. Eur. 2.4.14: Determination of Inorganic ImpuritiesPh. Eur. 2.4.20: Limit Test for Heavy Metals in ImpuritiesPh. Eur. 2.4.24: Related Substances by HPLC in APIsPh. Eur. 2.4.29: Limit Test for Sulfated Ash ImpuritiesPh. Eur. 2.5.13: Oxidizing Impurity TestsPh. Eur. 2.9.40: Uniformity of Dosage Units and Related ImpuritiesPh. Eur. 5.10: Control of Impurities in Substances for Pharmaceutical UsePh. Eur. 5.4: Impurities in Radiopharmaceutical PreparationsUSP <1010>: Analytical Data Integrity in Impurity ReportingUSP <1051>: Cleaning Validation Limits and Residual ImpuritiesUSP <1058>: Analytical Instrument Qualification for Impurity StudiesUSP <1078>: Good Manufacturing Practices for Impurity ReductionUSP <1085>: Evaluation of Impurity Method PerformanceUSP <1086>: Impurities in Drug SubstancesUSP <1088>: Forced Degradation Studies for Impurity CharacterizationUSP <1091>: Impurity Isolation and Characterization TechniquesUSP <1099>: Acceptable Analytical Performance CriteriaUSP <1121>: Bulk Pharmaceutical Chemicals and Impurity HandlingUSP <1151>: Pharmaceutical Dosage Forms and Impurity ConsiderationUSP <1191>: Stability Testing of Compounded PreparationsUSP <1222>: Terminal Sterilization Impact on ImpuritiesUSP <1224>: Transfer of Impurity Test ProceduresUSP <1225>: Validation of Compendial Procedures for ImpuritiesUSP <1226>: Verification of Compendial Procedures for Impurity DetectionUSP <1231>: Water for Pharmaceutical Purposes and Impurity EffectsUSP <1232>: Water Activity and Impurity StabilityUSP <1241>: Capsules and Shell Impurity InteractionUSP <1251>: Weighing on Analytical Balances for Micro-ImpuritiesUSP <161>: Transdermal Delivery Systems and Impurity ControlUSP <197>: Spectrophotometric Identification of ImpuritiesUSP <233>: Elemental Impurities Profiling Using ICP-MSUSP <41>: Balances Used for Impurity Weight DeterminationUSP <466>: Identification and Quantification of DegradantsUSP <467>: Residual Solvent Testing in APIs and ExcipientsUSP <476>: Impurity Profiling for New Drug ApplicationsUSP <621>: Chromatography Conditions for Impurity IdentificationUSP <730>: Plasma Spectrochemistry for Impurity ProfilingUSP <791>: pH Determination Impact on Impurity SolubilityUSP <797>: Sterile Compounding and Impurity ControlUSP <800>: Hazardous Drug Handling Based on Impurity RiskUSP <851>: Spectrophotometry and Light Scattering for ImpuritiesUSP <853>: Atomic Absorption Spectroscopy for Trace ImpuritiesUSP <857>: UV-Vis Spectroscopy for Impurity QuantificationUSP <85>: Bacterial Endotoxin Limits Related to Impurity SafetyUSP <891>: Nuclear Magnetic Resonance (NMR) for Structural ElucidationUSP <905>: Content Uniformity Related to ImpuritiesUSP <905>: Uniformity of Dosage Units Affected by ImpuritiesUSP <941>: Characterization of Impurity Solubility and pKaWHO TRS 970 Annex 2: Impurity Control in Medicines

USP <1031>: The Biocompatibility of Materials and Impurities Laboratory Testing Service

Provided by Eurolab: Ensuring Product Safety and Compliance

As a quality manager or engineer, regulatory compliance officer, business owner, or technical professional, ensuring the safety and biocompatibility of materials and impurities in your products is crucial. This comprehensive guide will walk you through the intricacies of USP <1031>: The Biocompatibility of Materials and Impurities testing services provided by Eurolab, a leading laboratory testing service provider.

USP <1031> is a standard developed by the United States Pharmacopeia (USP) to evaluate the biocompatibility of materials and impurities in pharmaceutical products. This standard applies to all materials used in the manufacture, packaging, or storage of pharmaceuticals, including active pharmaceutical ingredients, excipients, containers, closures, and labeling.

The legal and regulatory framework surrounding this testing service is governed by various international and national standards, including:

  • ISO 10993-1:2018 Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process

  • ASTM F748-15 Standard Practice for Selecting Generic Biological Test Methods for Materials and Devices

  • EN 556-2:2016 Sterilization requirements for medical devices, including single-use or reusable sterilizable medical devices

  • TSE ISO/TS 16775:2014 Implantable medical devices Particular requirements for the application of ISO 13485 to the design and manufacture of implantable medical devices

    • These standards provide a framework for evaluating the biocompatibility of materials and impurities in pharmaceutical products, ensuring their safety for human use.

    The specific test is needed and required due to several business and technical reasons:

  • Ensure product safety and reliability

  • Prevent adverse reactions or injuries caused by material or impurity exposure

  • Comply with international and national regulations

  • Maintain product quality and consistency

  • Enhance customer trust and confidence

    • Consequences of not performing this test include:

  • Product recalls and withdrawals

  • Loss of market share and revenue

  • Damage to brand reputation and credibility

  • Compliance issues and regulatory penalties

    • Industries and sectors that require this testing include:

  • Pharmaceutical manufacturing

  • Medical device industry

  • Biotechnology and biopharmaceuticals

  • Cosmetics and personal care products

    • The USP <1031> test is conducted using a step-by-step approach:

    1. Sample Preparation: Collecting, preparing, and storing the sample according to standard protocols.

    2. Testing Equipment and Instruments: Utilizing specialized equipment, such as spectrophotometers, chromatography systems, or microscopes, depending on the specific testing requirements.

    3. Testing Environment Requirements: Maintaining a controlled environment with precise temperature, humidity, and pressure settings.

    4. Measurement and Analysis Methods: Conducting measurements using various techniques, including spectroscopy, chromatography, microscopy, or other specialized methods.

    The test report is detailed and comprehensive, including:

  • Test method description

  • Sample preparation procedures

  • Testing parameters and conditions

  • Measurement and analysis results

  • Calibration and validation data

  • Quality control measures during testing

    • Eurolabs reporting standards and formats comply with international regulations and industry guidelines. Results are validated and verified to ensure accuracy and reliability.

    Performing the USP <1031> test offers numerous benefits, including:

  • Risk Assessment and Mitigation: Identifying potential risks associated with material or impurity exposure.

  • Quality Assurance and Compliance: Ensuring product safety and regulatory compliance.

  • Competitive Advantages: Demonstrating commitment to quality and customer trust building.

  • Cost Savings and Efficiency Improvements: Reducing the likelihood of recalls, withdrawals, and regulatory penalties.

    • Eurolab is a leading laboratory testing service provider with:

  • Expertise and experience in this field

  • State-of-the-art equipment and facilities

  • Qualified and certified personnel

  • International recognition and partnerships

  • Accreditation and certification details

  • Quality management systems and procedures

  • Customer service and support capabilities

    • Additional Requirements

  • Use professional and technical language appropriate for laboratory testing.

  • Include relevant technical specifications and parameters.

  • Provide industry-specific examples and case studies.

  • Include statistical data and research findings where applicable.

    • By following this comprehensive guide, you will gain a deeper understanding of the USP <1031>: The Biocompatibility of Materials and Impurities testing service provided by Eurolab. This article serves as a complete reference guide for ensuring product safety and compliance in the pharmaceutical industry.

    ---

    References

  • United States Pharmacopeia (USP). (2020). <1031> Biocompatibility of materials and impurities.

  • International Organization for Standardization (ISO). (2018). ISO 10993-1:2018 Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process.

  • American Society for Testing and Materials (ASTM). (2015). ASTM F748-15 Standard Practice for Selecting Generic Biological Test Methods for Materials and Devices.

  • European Committee for Standardization (CEN). (2016). EN 556-2:2016 Sterilization requirements for medical devices, including single-use or reusable sterilizable medical devices.

    • ---

    Note: This comprehensive guide is a summary of the USP <1031> standard and does not replace the original document. For detailed information and specific testing requirements, consult the USP <1031> standard and relevant regulations.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    CONTACT US +902127020000

    Latest News

    View all

    Eurolab Successfully Renews ISO 17025 Accreditation

    Read More

    Expanded Cosmetic Safety Testing Portfolio Now Available at Eurolab

    Read More

    Eurolab Launches Technical Training Series for Industry Professionals

    Read More

    JOIN US
    Want to make a difference?

    Careers